Welcome to our dedicated page for Neogenomics news (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics stock.
NeoGenomics, Inc. (NASDAQ: NEO) is a cancer diagnostics company focused on oncology genetics testing and information services. This news page aggregates company announcements, conference presentations, financial updates, and other disclosures that relate to NeoGenomics’ role in precision oncology and testing laboratories.
Readers can find earnings and financial news, including quarterly and preliminary full-year revenue updates furnished through press releases and Form 8-K filings. These items describe trends in clinical test volumes, next-generation sequencing (NGS) revenue, and other aspects of the company’s oncology testing business.
The news feed also features scientific and clinical research updates. NeoGenomics regularly announces data presentations at major oncology and hematology meetings, such as the San Antonio Breast Cancer Symposium, the American Society of Hematology Annual Meeting, the International Society of Liquid Biopsy Annual Congress, and the European Society for Medical Oncology Congress. These updates often highlight molecular residual disease (MRD) studies using RaDaR assays, comprehensive genomic profiling in myeloid malignancies, and liquid biopsy-based genomic profiling across solid tumors.
In addition, investors and clinicians can follow corporate and governance developments, including board appointments, executive transitions, and participation in investor conferences. Together, these news items provide a view into how NeoGenomics advances its oncology diagnostics platforms, supports pharmaceutical partners and academic collaborators, and manages its public-company responsibilities. For ongoing insight into NEO stock-related developments and oncology testing initiatives, this page serves as a centralized news resource.
NeoGenomics (NASDAQ: NEO) announced that its PanTracer LBx liquid biopsy test received Medicare coverage through CMS MolDX under LCD L38043 on March 16, 2026. This decision enables Medicare patients to access a blood-based comprehensive genomic profiling option evaluating more than 500 genes, including MSI and bTMB, with a seven-day turnaround.
The test is performed in NeoGenomics' CLIA-certified California lab and can be ordered standalone, as a reflex, or concurrently with tissue testing, expanding access to precision oncology in community settings.
NeoGenomics (NASDAQ: NEO) launched RaDaR ST, a circulating tumor DNA (ctDNA) assay for detecting molecular residual disease (MRD) across multiple solid tumors. RaDaR ST tracks up to 48 tumor-specific variants with an LOD95 of 11 ppm, combines whole-exome sequencing and bioinformatics, and is validated in breast and HPV-negative head and neck studies. The assay is approved by Medicare for initial launch indications, with two additional reimbursement indications submitted. NeoGenomics cited a >$20 billion addressable MRD market growing ~30% annually and 10% current penetration.
NeoGenomics (NASDAQ:NEO) will participate in two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference and Leerink Global Healthcare Conference.
Fireside chats are scheduled for March 3, 2026 at 1:10 PM ET and March 10, 2026 at 4:20 PM ET. Live and archived webcasts will be available on the company Investor Relations site.
NeoGenomics (Nasdaq: NEO) reported fourth-quarter and full-year 2025 results. Full-year revenue rose 10% to $727 million and Q4 revenue rose 11% to $190 million. Adjusted EBITDA was positive $43 million for 2025. The company resolved RaDaR ST patent litigation and provided FY2026 guidance of $793–$801 million revenue and improved net loss guidance of $(63)–$(50) million.
Clinical revenue grew 15% (13% excluding Pathline); NGS volumes grew ~22% for the year, and cash totaled $160 million at year-end.
NeoGenomics (NASDAQ: NEO) launched PanTracer Pro, an integrated diagnostic offering for advanced-stage solid tumors combining broad genomic profiling, diagnosis-directed IHC, and ancillary tests.
The test covers more than 500 cancer-related genes, has an expected turnaround time of 8–10 days, and can automatically reflex to PanTracer LBx liquid biopsy when tissue is insufficient.
NeoGenomics (NASDAQ: NEO) will report its fourth quarter and full year 2025 financial results before U.S. markets open on Tuesday, February 17, 2026. Management will host a webcast and conference call at 8:30 a.m. ET to discuss results and recent highlights. The live webcast is available via the Investor Relations website at ir.neogenomics.com and will be archived for replay shortly after the call. Telephone access is available at (888) 506-0062 (domestic) or (973) 528-0011 (international) with participant access code 825997. Attendees are asked to dial in at least five minutes before the call.
NeoGenomics (NASDAQ:NEO) expects preliminary unaudited Q4 2025 revenue of ~$190 million (≈11% YoY) and preliminary unaudited full‑year 2025 revenue of ~$727 million (≈10% YoY). The company noted these are preliminary estimates and subject to change pending year‑end close and audit; final results will be reported on the company’s February 2026 earnings call. NeoGenomics also announced a CFO succession: Abhishek Jain joins as EVP on January 12, 2026, will become CFO on March 2, 2026, as current CFO Jeff Sherman transitions and retires April 14, 2026.
NeoGenomics (NASDAQ:NEO) will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Management is scheduled to present and take part in a Q&A session on Tuesday, January 13, 2026 at 5:15 p.m. PT / 8:15 p.m. ET. Interested parties can view live and archived webcasts on the company’s Investors site at ir.neogenomics.com. The presentation will cover recent company developments and offer a management Q&A for investors and analysts.
NeoGenomics (NASDAQ: NEO) appointed diagnostics and lab services veteran John P. “Jack” Kenny to its Board of Directors, effective December 30, 2025, filling the seat of Alison Hannah, MD, who is rotating off after more than ten years.
Mr. Kenny brings 30+ years of executive, commercial, and operational experience, most recently as CEO and president of Meridian Bioscience, and prior senior roles at Siemens Healthcare, Becton Dickinson, Quest, Abbott, and Leica. The board expects his commercial leadership to support growth in NGS and MRD cancer testing and community-setting expansion.
NeoGenomics (NASDAQ:NEO) said Natera voluntarily dismissed its appeal in ongoing RaDaR patent litigation, leaving in place an August 2025 North Carolina federal court ruling in NeoGenomics’ favor.
The District Court granted NeoGenomics’ motion for summary judgment, held Natera’s asserted patent claims invalid as ineligible subject matter, dismissed Natera’s claims with prejudice, and entered a declaratory judgment of invalidity for both asserted patents. NeoGenomics said the dismissal allows it to focus on a full U.S. clinical launch of RaDaR ST in Q1 2026.